Tri Locum Partners LP Has $5.15 Million Holdings in GeneDx Holdings Corp. $WGS

Tri Locum Partners LP lessened its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 54.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 58,145 shares of the company’s stock after selling 69,422 shares during the quarter. GeneDx makes up approximately 2.6% of Tri Locum Partners LP’s investment portfolio, making the stock its 14th largest holding. Tri Locum Partners LP owned approximately 0.21% of GeneDx worth $5,150,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of GeneDx by 151.7% during the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock worth $39,000 after buying an additional 264 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of GeneDx during the 4th quarter worth approximately $35,000. US Bancorp DE grew its position in shares of GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after buying an additional 548 shares during the period. Comerica Bank acquired a new stake in shares of GeneDx during the 4th quarter worth approximately $50,000. Finally, KBC Group NV acquired a new stake in shares of GeneDx during the 1st quarter worth approximately $81,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Price Performance

Shares of WGS opened at $129.19 on Thursday. GeneDx Holdings Corp. has a 12-month low of $28.86 and a 12-month high of $130.34. The business’s fifty day moving average is $97.49 and its 200 day moving average is $88.65. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. The stock has a market cap of $3.71 billion, a P/E ratio of 2,583.80 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The company had revenue of $102.69 million for the quarter, compared to analysts’ expectations of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other GeneDx news, CFO Kevin Feeley sold 5,278 shares of the firm’s stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $93.00, for a total transaction of $490,854.00. Following the transaction, the chief financial officer directly owned 3,392 shares in the company, valued at approximately $315,456. This trade represents a 60.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jason Ryan sold 38,072 shares of the firm’s stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total value of $4,846,565.60. Following the transaction, the director owned 103,284 shares in the company, valued at approximately $13,148,053.20. This trade represents a 26.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 561,633 shares of company stock valued at $67,530,714 in the last 90 days. Insiders own 29.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on WGS shares. Jefferies Financial Group raised shares of GeneDx from a “hold” rating to a “buy” rating and set a $80.00 price objective for the company in a research report on Friday, May 9th. Piper Sandler set a $120.00 price objective on shares of GeneDx and gave the stock an “overweight” rating in a research report on Monday, August 4th. Guggenheim reaffirmed a “buy” rating and set a $115.00 price objective (up previously from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Wall Street Zen upgraded GeneDx from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Finally, TD Securities cut their target price on GeneDx from $135.00 to $110.00 and set a “buy” rating on the stock in a report on Thursday, May 1st. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and a consensus price target of $101.63.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.